GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an

BioNTech’s plan to shed 22% of its workforce and stop COVID-19 vaccine production has earned it a rebuke from Germany’s third-largest labour union.

GSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio.

CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech

Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears